Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer by Strauss, Bryan E. et al.
Perspectives for cancer immunotherapy mediated by
p19Arf plus interferon-beta gene transfer
Bryan E. Strauss,* Gissele Rolemberg Oliveira Silva, Igor de Luna Vieira, Otto Luiz Dutra Cerqueira,
Paulo Roberto Del Valle, Ruan Felipe Vieira Medrano, Samir Andrade Mendonc¸a
Laborato´rio de Vetores Virais, Centro de Investigac¸a˜o Translacional em Oncologia, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das
Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Strauss BE, Silva GR, Vieira IL, Cerqueira OL, Del Valle PR, Medrano RF, Mendonc¸a SA. Perspectives for cancer immunotherapy mediated by p19Arf plus
interferon-beta gene transfer. Clinics. 2018;73(suppl 1):e479s
*Corresponding author. E-mail: bstrauss@usp.br / bryan.strauss@hc.fm.usp.br
While cancer immunotherapy has gained much deserved attention in recent years, many areas regarding the
optimization of such modalities remain unexplored, including the development of novel approaches and the
strategic combination of therapies that target multiple aspects of the cancer-immunity cycle. Our own work
involves the use of gene transfer technology to promote cell death and immune stimulation. Such immunogenic cell
death, mediated by the combined transfer of the alternate reading frame (p14ARF in humans and p19Arf in mice)
and the interferon-b cDNA in our case, was shown to promote an antitumor immune response in mouse models
of melanoma and lung carcinoma. With these encouraging results, we are now setting out on the road toward
translational and preclinical development of our novel immunotherapeutic approach. Here, we outline the
perspectives and challenges that we face, including the use of human tumor and immune cells to verify the response
seen in mouse models and the incorporation of clinically relevant models, such as patient-derived xenografts and
spontaneous tumors in animals. In addition, we seek to combine our immunotherapeutic approach with other
treatments, such as chemotherapy or checkpoint blockade, with the goal of reducing dosage and increasing efficacy.
The success of any translational research requires the cooperation of a multidisciplinary team of professionals
involved in laboratory and clinical research, a relationship that is fostered at the Cancer Institute of Sao Paulo.
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’ INTRODUCTION
The progression of cancers depends, in part, on the ability
of tumor cells to escape immunosurveillance (1). Tumor
cells accomplish this by a variety of mechanisms, collec-
tively termed immunoediting, which include the hijacking
of signaling events to promote an immunosuppressive micro-
environment and selecting tumor cells that are no longer
recognized by the immune system (2,3). The goal of immuno-
therapy is to enhance, if not reboot, the cancer-immunity cycle,
starting with tumor cell killing by an immunogenic mechan-
ism, enhancing the function of antigen-presenting cells (APCs)
and stimulating cytolytic and helper T (Th) cell responses, thus
completing the cycle (4). Each round through the immunity
cycle may amplify the antitumor immune response since the
killing of the tumor cells may release additional antigens that
would then contribute to broaden the T cell repertoire.
Immunotherapies that directly target tumor cell killing
typically rely on the induction of immunogenic cell death
(ICD). Such therapeutic approaches include treatment with
certain chemotherapeutic agents, such as anthracyclines
and oxaliplatin, or the application of oncolytic viruses.
These agents promote the release of tumor antigens in
conjunction with the release of signals that activate APCs,
including ATP, high mobility group box-1 (HMGB1) and
interferon-b (IFNb), and the exposure of calreticulin on the
surface of tumor cells (5). Alternatively, tumor vaccines
may provide one or more critical antigens and may even
deliver ex vivo-modified dendritic cells (DCs) to stimulate
an antitumor immune response. Checkpoint blockade typi-
cally relies on the use of monoclonal antibodies to reverse
the negative regulation of T cells due to their expression
of inhibitory molecules, such as cytotoxic T lymphocyte-
associated molecule-4 (CTLA-4) or programmed cell death
protein 1 (PD-1) (4). Alternatively, adoptive cell transfer
(ACT) can be used, where autologous T cells may be selected/
modified ex vivo, expanded, and returned to the patient
to induce tumor cell killing. In particular, chimeric antigen
receptor (CAR) T cells have recently gained much attention,
especially for the treatment of B cell leukemias (6) and
lymphomas (https://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm 581216.htm). Since each of these
immunotherapies targets particular points in the cancer-
immunity cycle, their combination may also lead to an even
greater efficacy (4).DOI: 10.6061/clinics/2018/e479s
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The promise of immunotherapies has justifiably gained
considerable attention over the past few years. However, the
role of gene transfer/gene therapy in this setting has not yet
been fully explored. For example, oncolytic viruses induce
cell killing as a result of viral replication leading to cell lysis
but do not necessarily encode a transgene, such as granu-
locyte macrophage-colony stimulating factor (GM-CSF). The
application of oncolytic viruses is often referred to as viro-
therapy, a close cousin of gene therapy, but not a gene transfer
approach per se. In fact, Imlygic (talimogene laherparepvec,
T-Vec, an oncolytic herpes virus encoding GM-CSF) was
considered a first in-class product when it was approved by the
U.S. Food and Drug Administration (FDA) (7). The recently
approved CAR T cell approaches Kymriah and Yescarta for the
treatment of B cell leukemia and some large B cell lympho-
mas, respectively (6), (https://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm581216.htm) have been
classified by the FDA as cell-based gene therapies; that is, the
gene transfer aspect is not performed directly in the patient,
but a vector encoding the CAR is applied to T cells ex vivo.
To the best of our knowledge, no in situ cancer gene
therapy approach that acts as an inducer of ICD, character-
ized by the release of ATP, calreticulin and HMGB1, has been
described to date. Nevertheless, gene therapy approaches
that induce an immune response are known. The transfer of
the thymidine kinase (TK) gene derived from the herpes
simplex virus by means of nonreplicating adenoviral vectors
(Ad-TK) has been extensively explored (8). In transduced
tumor cells, TK, in conjunction with cellular enzymes, con-
verts prodrugs (ganciclovir, valacyclovir, acyclovir) into their
active forms to block DNA replication and induce cell death.
The Ad-TK approach, also termed gene-mediated cytotoxic
immunotherapy (GMCI), is known not only for the asso-
ciated bystander effect but also for its ability to stimulate an
antitumor immune response (8). Several clinical trials are
being or have been performed, including a phase III trial for
the treatment of high-grade glioma, where time to death, but
not overall survival, was increased (9).
Also in development are approaches that combine GMCI
with other therapeutics that boost the antitumor response,
including the association of Ad-TK with FMS-like tyrosine
kinase 3 ligand (FLT3L) gene transfer (10). A particularly
interesting approach is the use of Toca 511 (vocimagene
amiretrorepvec), a nonlytic, replicating retroviral vector that
spreads among tumor cells for the delivery of the cytosine
deaminase (CD) gene, which converts 5-fluorocytosine into
5-fluorouracil (5FU) and has been shown stimulate anti-
tumor immune responses (11). In a phase I trial, compared
to an external control, Toca 511 significantly improved the
overall survival of patients with high-grade glioma (12).
While a variety of gene transfer approaches can be con-
sidered immunotherapies, further improvements may result
in more robust responses in a larger number of patients.
A role for the p19Arf and IFNb gene transfer in
cancer immunotherapy
Our work has focused on cancer gene therapy using
adenovirus-mediated gene transfer to elicit both cell death
and activation of an immune response against tumors. Here,
we will provide an overview of one immunotherapeutic
approach that utilizes a specialized vector to deliver the cDNA
encoding the alternate reading frame (ARF; p14ARF in humans
and p19Arf in mice) and IFNb proteins to cancer cells.
Our group is also developing additional modalities descri-
bed elsewhere, including a review in this issue of Clinics,
which involve the use of our specialized vector for the
transfer of the cDNA encoding the tumor suppressor p53.
The following discussion will provide an overview of the
development of our gene transfer approach and of the
evidence suggesting that the transfer of p19Arf and IFNb
indeed acts as an immunotherapy in mouse models of
melanoma and lung cancer.
The antitumor activities of p53 are frequently related to
its role as a regulator of transcription of a variety of target
genes, which in turn direct cell death, inhibit the cell cycle
and DNA repair, and block angiogenesis, among others
(13,14). Although quite complex, key regulators of p53 include
the human homolog of murine double minute-2 (HDM2),
which directs p53 for degradation, and p14ARF, which
disrupts the interaction between MDM2 and p53, thus freeing
p53 to act (15). Despite variable reports, published data
indicate that up to 90% of melanomas retain p53 in the wild-
type form (16). However, p53 is essentially dormant due to the
loss of agonistic or gain in antagonistic factors, including the
lack of p14ARF in 50% and the overexpression of HDM2 in
56% of melanomas (16-18). We reason that the endogenous
wild-type p53 (p53wt) may be activated in response to gene
transfer and that the activated p53, a powerful transcription
factor, may be harnessed to not only act as a tumor suppressor
but also drive the expression of the transgene encoded by the
gene transfer vector as described below. Thus, we expect to
establish dynamic interactions among the gene transfer vector,
the therapeutic gene(s) and endogenous p53.
Our gene transfer platform involves a nonreplicating,
recombinant, serotype 5 adenovirus (Ad5) in which trans-
gene expression is controlled by a p53-responsive promoter,
PGTxb, called PG for simplicity. The chimeric promoter
includes 13 copies of a p53-responsive element (PG), a TATA
box (Tx) and the first intron of the rabbit b-globin gene (b), as
previously detailed (19). The PG promoter can be used to
drive the expression of the p53 cDNA, establishing a positive
feedback mechanism that is initiated due to leaky transcrip-
tion even in p53-null cells (20,21). Alternatively, the PG pro-
moter may be employed to drive the transcription of any
gene of choice as long as p53 is present in the cell. Expression
from the PG promoter is 5 to 7 times higher than that seen
from typical, constitutive promoters, such as the cytomega-
lovirus (CMV) immediate early promoter enhancer or the
retroviral long terminal repeat (LTR) (19-21). In fact, we have
developed three viral platforms, namely, retrovirus, adeno-
virus and adeno-associated virus, in which transgene expres-
sion is dependent on p53 (19,22,23). Such vectors are expected
to have utility in not only models of cancer gene therapy
but also other conditions that involve cellular stress, such as
hypoxia (22,24).
After developing the PG vectors, our next task was to
use these to deliver the p19Arf cDNA and assess whether
endogenous p53 could be activated. Indeed, the transfer of
p19Arf, but not p53, resulted in increased p53 activity in B16
mouse melanoma cells (with endogenous p53wt). However,
we noted that this activation was accentuated when gene
transfer was combined with chemotherapeutic agents, result-
ing in increased cell death both in vitro and in vivo (25).
Since we wished to maximize cell death and induce immune
stimulation, we decided to perform simultaneous transfer
of p19Arf and IFNb because the p53/Arf and type I inter-
feron (IFNa/b) pathways have been indicated to cooperate.
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The presence of p53 has been shown to increase cell death
and minimize viral replication in cells treated with recom-
binant type I interferon protein (rIFN) (26). Interestingly,
one report form the literature suggests that ARF, not p53,
is actually the critical factor that mediates the apoptotic
response to rIFN (27). Such interactions are to be expected
since both type I IFN and the p53/Arf pathways play
important roles in regulating cell death (28). Indeed, we
noted that compared to single gene transfer, the combined
transfer of p19Arf and IFNb (p19Arf + IFNb) mediated by
our p53-responsive Ad5 vector resulted in enhanced B16
cell death regardless of in vitro or in vivo application. In a
mouse model of in situ gene therapy (that is, injection of
viral particles directly into the tumor mass), only the com-
bined gene transfer approach was associated with extensive
tumor cell killing and prolonged survival, although IFNb
gene transfer could also delay tumor progression (29). From
this study, we learned that the combined, but not indivi-
dual, gene transfer was especially effective for the induction
of cell death.
In a later study, we examined both the critical aspects of
the adenovirus-mediated gene transfer and the specific
mechanism of cell death in response to p19Arf and IFNb
gene transfer. In this work, improvements to vector design
involved the use of the RGD tripeptide included in the knob
domain of the adenovirus fiber protein, thus broadening the
spectrum of cells that may be transduced since virus-cell
interaction depends on integrins but not the coxsackievirus
and adenovirus receptor (30-32). We also explored the use
of a single vector for the simultaneous transfer of the
p19Arf and IFNb cDNA, finding that both co-transduction
and IRES-mediated expression of two proteins from a single
transcript were equally effective (32). As expected, combined,
but not single, gene transfer resulted in enhanced killing of
B16 cells. However, we uncovered an important bystander
effect, where the presence of exogenous p19Arf was shown
to sensitize the melanoma cells to secreted IFNb produced
by neighboring cells that had received the IFNb vector. In
addition, we provided functional and molecular evidence
indicating that the presence of the adenoviral vector itself
was important for mediating the antiviral response that
contributed to cell killing. In other words, gene transfer was
more effective than the pharmacological activation of the
p53/Arf and type I IFN pathways (32).
The mechanism of cell death was also explored, revealing
that apoptosis was not responsible for cell death in response
to combined gene transfer, since caspase activity was not
required for cell killing. Instead, we observed that combined,
but not individual, gene transfer activated critical mediators
of necroptosis. Moreover, only combined gene transfer was
associated with the presentation of all three classic markers
of ICD, namely, calreticulin, ATP and HMGB1. As expected,
involvement of the p53 pathway was revealed by elevated
levels of p53 target genes (p21/Cdkn2a, Puma, Phlda2), as
well as p53 itself, when B16 cells were treated with combined
gene transfer both in vitro and in vivo. Interestingly, com-
bined gene transfer in vivo in a model of in situ gene therapy
was associated with vesicular and perinuclear staining of
LC3b, suggesting a potential role for autophagy in our model.
Microarray analysis of B16 cells after ex vivo gene transfer
revealed increased expression of genes associated with the
immune response, p53 activity, cell death and antiviral response
and decreased expression of cell cycle-related transcripts.
Therefore, the multimodal cell death mechanism was consistent
with necroptosis associated with the release of ICD markers
and an antiviral response (31,32).
The cellular response to p19Arf + IFNb gene transfer
shows that our approach is effective at killing tumor cells
by a mechanism that is expected to promote an antitumor
immune response. In another study using the B16 mouse mela-
noma cell line, several parameters of this immune response
were revealed. For example, B16 cells were transduced ex vivo,
and then the dying cells were applied as a prophylactic vaccine
in syngeneic immunocompetent mice. Later, naïve B16 cells
were implanted in the opposite flank, representing a tumor
challenge. While vaccinations involving IFNb gene transfer
alone or in combination with p19Arf were effective in slowing
challenge tumor growth, only the combined approach was
significantly associated with increased survival (33). With
optimization, tumor progression at the vaccination site could
be completely eliminated in both immunocompetent C57BL/
6 or T cell-deficient BALB/c nude mice (both endowed with
high activity of natural killer (NK) cells); however, this
protection was lost in innate and adaptive immunodeficient
NOD-SCID mice, suggesting a critical involvement of NK
cells. Gene expression analysis revealed substantial upre-
gulation of Ulbp1, IL-16, Killer/DR5 and FAS/Apo1, which
are critical factors for the NK cell response, albeit only in
association with the combined gene transfer approach. Evi-
dence for a de facto immune response was revealed by the
depletion of either CD4+ or CD8+ T cell populations, which
reversed the protective effect of the prophylactic vaccine. Mor-
eover, the vaccination approach promoted a Th1 cytokine
profile. Strikingly, the optimized prophylactic vaccination
protocol provided significant protection against tumor
growth even when the challenge was applied 70 days post-
vaccination. Alternatively, subcutaneous Tm1 tumors were
first established before the application of a therapeutic
vaccine consisting of dying Tm1 cells in response to ex vivo
gene transfer and resulted in a significant reduction of tumor
progression only in response to the combined p19Arf+ IFNb
treatment (33). In other words, our gene transfer approach
with p19Arf + IFNb can be classified as immunotherapy.
Although the vaccination approach involving p19Arf +
IFNb gene transfer provided evidence for an effective anti-
tumor immune response, we also wished to explore whether
in situ cancer gene therapy using our vectors can serve as
immunotherapy. To this end, we first confirmed the induc-
tion of ICD in Lewis lung carcinoma (LLC, mouse lung
carcinoma, p53wt) cells only in response to the combined
gene transfer (34). We then showed that a prophylactic
vaccination model using LLC cells in C57BL/6 mice was
especially effective in slowing challenge tumor growth when
the vaccine cells had been treated with the combination of
p19Arf+ IFNb. In situ gene therapy showed that both IFNb
alone and in combination with p19Arf could significantly
delay tumor progression, although the association of cisplatin
with gene therapy resulted in nearly complete tumor inhi-
bition only in the presence of p19Arf + IFNb. Indeed, in situ
gene therapy followed by subcutaneous injection of naïve LLC
cells resulted in greatly enhanced inhibition of the challenge
tumor when the primary tumor had been treated with
p19Arf + IFNb rather than IFNb alone. In addition, micro-
array analysis of tumors treated with in situ gene therapy
revealed a gene signature consistent with an immune response
and chemotactic enrichment, suggesting the presence of neu-
trophils and CD8+ T cells. In one study, the presence of
infiltrating neutrophils was confirmed, and depletion of
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the granulocyte population reversed the benefit of in situ
gene therapy (34). In this study, we revealed, among other
findings, that our in situ gene transfer approach initiates
an antitumor immune response and can be considered
immunotherapy.
Taken together, these results reveal that the p19Arf +
IFNb gene transfer strategy promotes an immune response
that includes the participation of NK cells, neutrophils, a Th1
response and, importantly, CD4+ and CD8+ T cells (31,35).
The cellular response to combined gene transfer has been
shown to induce ICD and, specifically in the case of B16, cell
death consistent with necroptosis (31,35). While the studies
performed to date have been interesting, some developments
remain before we can affirm that our approach indeed holds
promise for clinical application.
’ CHALLENGES AND PERSPECTIVES FOR THE
P19ARF + IFNb IMMUNOTHERAPY
As described in the following sections, we are looking
forward to the next phase of our investigation where we face
the challenge of further developing our approach and incor-
porating more clinically relevant models. In other words, we
are poised to advance on our journey along translational
research (Figure 1). We are concerned with the interactions of
the p19Arf + IFNb gene transfer approach with respect to
Figure 1 - Schematic representation of the challenges and perspectives of continuing along the road of translational research. Critical
milestones include testing our approach in human cells, including patient-derived tumor and immune cells, and models of spontaneous
tumors, such as canine melanoma. In addition, the combination of our approach with chemotherapy or other immunotherapies may
enhance efficacy. Virus production following good manufacturing practices (GMP) is critical for providing not only larger quantities of
vectors but also biological agents of pharmaceutical quality.
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not only the tumor cell response but also the impact on the
tumor microenvironment. While the use of mouse models
aids in such studies, especially when the immune response
is to be examined, it is critical to determine the behavior
of human tumor cells and even the activation of human
immune cells upon p14ARF + human IFNb (hIFNb) gene
transfer. Another critical step towards the preclinical evalua-
tion of our immunotherapeutic approach involves the use of
alternative models of tumor treatment.
Potential impact of p19Arf + IFNb on tumor
angiogenesis
Since both the p53/Arf and IFN pathways are known to
impact the tumor microenvironment, the study of such
interactions may show the potential of our gene therapy
approach in inhibiting angiogenesis and possibly metastasis.
Tumor cells, nontumor cells, and noncellular components are
partners working together for the survival of solid cancers
(36). Nontumor cells are important components of the micro-
environment, promoting tumorigenesis through a variety of
cell types and mechanisms (37). The network of blood vessels
is a critical component of the tumor microenvironment and
provides oxygen, nutrients, immune surveillance and a route
for metastasis, essentially fueling tumorigenesis (38). Failure
of many cancer treatments can be explained, in part, by
mechanisms that include poor biodistribution of drugs and
an unfavorable tumor microenvironment (39). Thus, the
impact of novel treatments on the tumor microenvironment
must not be overlooked.
In addition to the well-known tumor suppressor activity of
p53, its influence can reach beyond the single tumor cell (40).
Depending on whether it is wild type or mutant, the p53
protein can modulate the extracellular matrix (41,42) and
induce the secretion of proinflammatory proteins (43-45) and
lactate, resulting in the acidification of the tumor boundary
(46,47). p53 also coordinates the crosstalk between cancer
and noncancer cells (48,49).
A p53-dependent and independent role for p19Arf in
the angiogenic switch has been shown to accelerate tumor
growth (50). Alternatively, p14ARF can sequester hypoxia-
inducible factor 1a (HIF-1a), thus inhibiting HIF-1 transacti-
vation in a p53-independent manner (51). Notably, p14ARF
has been shown to suppress angiogenesis by blocking the
translation of the vascular endothelial growth factor (VEGF)-
A transcript (52). Thus, Arf can play a role in inhibiting
tumor angiogenesis.
Type I IFNs are also recognized for their ability to block
angiogenesis (28). For example, IFNb has been shown to
upregulate inducible nitric oxide synthase (iNOS), thus
blocking angiogenesis and tumor progression in a xenograft
model of human prostate carcinoma (53). IFNa and IFNb
have also been shown to block the production of essential
mediators of angiogenesis, including basic fibroblast growth
factor (bFGF), VEGF and interleukin (IL)-8 (28). Thus, each of
the central players in our gene transfer approach may nega-
tively impact tumor angiogenesis, but this point remains to
be experimentally tested.
Gearing up for the study of p14ARF + hIFNb gene
transfer in human cells
Despite good results in preclinical models, many promis-
ing candidate drugs do not successfully cross the bridge
between the bench and bedside (54). As discussed above,
the combined p19Arf + IFNb gene transfer approach trig-
gered cell death mechanisms with remarkable immunogenic
features, leading to reduced tumor burden and increased
survival in animal models, which are desirable character-
istics for any cancer therapeutics in development. Although
our gene transfer approach seems promising, the transla-
tion of these results from mouse models to human cells
represents a major step forward toward clinical relevance.
Mice and humans share many functional gene sequences
but greatly diverge with respect to transcriptional regulation
(55). Reliance on mouse models to predict human physiology
and response to therapy is severely limited, and a critical
step in closing this gap is the inclusion of studies performed
in human cells. While patient-derived xenograft (PDX) models
may be preferred (56), the use of established cell lines comes
with ease of use and a wealth of knowledge in the literature
about their genotype and response to various treatments. For
example, a variety of human melanoma cell lines with distinct
genotypes, especially with respect to p53, are widely available.
Nonetheless, the transition to human cell lines comes with
an additional task with respect to our gene transfer approach.
The cellular response to IFNb is species specific; that is, mouse
cells treated with human IFNb, or vice versa, will produce
distinct antiproliferative responses (57). Thus, we have to be
particularly careful to match the cDNA encoded in the vectors
with the species being treated. The assays described for B16
and LLC cells above used only mouse cDNA. To initiate tests
in human cells, a new set of vectors harboring human pro-
tein coding sequences must be constructed. Human cDNA
(p14ARF and hIFNb) encoded by the p53-responsive ade-
noviral vectors and applied to human melanoma cell lines
creates the opportunity to test the induction of cell death,
cooperation between the p53/Arf and IFN pathways and
the mechanism of cell death. Since human melanoma cell
lines are known to harbor either wild-type or mutant p53,
we would also have the opportunity to explore the specific
role of p53 in our gene transfer approach. For this, an addi-
tional set of vectors encoding human cDNA, with expres-
sion under the control of the constitutive CMV promoter,
will be required.
The new vector constructs encoding human cDNA with
either constitutive or p53-dependent expression will enable a
deeper investigation of the molecular basis of the approach,
including their behavior in cell culture and immunodeficient
animals, the study of the contribution of p53 to the cellular
response, and, possibly, their combined use with pharma-
cotherapeutic approaches.
Seeking clinical relevance: use of patient-derived
tumor samples
For decades, the number of established cell lines from
tumor tissues has sharply increased, and this has undoubt-
edly resulted in many advances in the understanding of
oncogenic mechanisms and the discovery of new targets for
therapeutic interventions (58,59). As mentioned above, our
own work has frequently employed established cell lines.
During the isolation of ex vivo immortalized cell lines from
normal tissues, some homeostasis mechanisms, such as
cell cycle control, need to be inhibited, either by mutations
of key genes or addition of growth factors in the culture
medium. In comparison, cell lines derived from tumor tissues
already exhibit these mechanisms, although often in a dere-
gulated fashion (60,61). In addition to being cultured in vitro,
5
CLINICS 2018;73(suppl 1):e479s Translational road to cancer immunotherapy
Strauss BE et al.
these cells can be inoculated into immunocompromised
animals to generate xenografts, which may be either hetero-
topic or orthotopic, providing the opportunity to study
these cells in vivo (62).
While models based on human cell lines in monolayer
cultures and their corresponding xenografts are widely used
in cancer research, many limitations exist regarding this
approach. Human cancers are known to have extremely
heterogeneous cell populations comprising both neoplastic
cells and stromal cells that actively contribute to tumor
progression (63-66). Additionally, samples derived from
different patients have unique sets of mutations, leading to
differences in several signaling pathways and individual
series of carcinogenic events (67). The establishment and
propagation of these cell lines over time imply that only
certain subpopulations will be selected, and the resulting
clonality may not be representative of the original tumor
heterogeneity (67,68). Therefore, the number of effective
therapeutic tools that emerge from studies using cultured
patient-derived cells is still small (59,69).
In contrast, PDXs involve the implantation of tumor
tissues from patients directly into immunocompromised
recipient mice (70). Unlike cancer cell lines, PDX models do
not require in vitro culture steps, thus avoiding the selection
of distinct cell populations and the exclusion of stromal
components. The in situ physiological conditions encoun-
tered by these grafted cells in host mice, such as oxygen
pressure, nutrients and metabolites, are similar to those
found at the site of the patient’s primary tumor. Experi-
mental data suggest that overall genomic and gene expres-
sion profiles of PDXs are representative of the patients of
origin and are stable throughout sequential in vivo genera-
tions (71).
Taking this into account, the establishment of each PDX is
individually performed, preserving intra- and intertumor
heterogeneity and providing a clear advantage when used
for oncologic drug discovery and preclinical development
(72). Evidence in the literature indicates success in predicting
personalized anticancer treatments previously investiga-
ted using PDX models (73-75). Through the PDX approach,
mutations in melanoma have been mapped in more detail,
which provides complementary diagnostic data with greater
predictive power to indicate the therapeutic approach to be
adopted (76,77).
Another important feature recapitulated by the PDX
model is the maintenance of a three-dimensional (3D) arr-
angement. Cells grown on a flat surface differ greatly from
their 3D counterparts in vivo because of reduced cell-cell and
extracellular matrix-cell interactions, a limitation already
encountered with the traditional model of cancer cell lines
(78-80). However, the culture model in 3D environments
represents an intermediate approach between traditional cell
culture and animal models, since it largely recapitulates the
architecture of tissues in vivo (81-83).
Given that samples from patients are generally scarce and
difficult to obtain, the use of 3D culture models enable the
use of traditional cancer cell lines, prior to PDX models, for
the standardization of viral infection kinetics, pharmacoki-
netics, molecular biology, biochemistry and imaging techniques.
In addition, 3D cultures are less costly and labor-intensive than
animal studies and should be prioritized at a preliminary stage.
Experimental data show that the pattern of gene expression,
mRNA splicing, intracellular signaling, cytoskeletal organiza-
tion and secretion profile of cells grown in 3D cultures more
closely resemble what is observed in vivo than when grown
in two-dimensional (2D) cultures (84-88).
Initially, 3D cell cultures were derived from breast devel-
opment studies and breast cancer models (89). Later, these
methods were adapted for a variety of cells derived from
different organ systems (90). Melanoma spheroids grafted in
collagen gel matrix reproduce the architecture of a tumor
encountered in vivo, including a gradient of oxygen and
nutrients and a hypoxic and necrotic central zone (90,91). In
this model, tumor heterogeneity is recreated in a manner
similar to that found in patients, where only cells growing at
the periphery have differential activity of the extracellular
signal-regulated kinase (ERK). Consequently, small-molecule
inhibitors of the mitogen-activated protein kinase (MAPK)
pathway do not affect cells in the core of the spheroid (92,93).
This observation highlights important implications that must
be considered for the translation of novel targets for future
therapies, both in terms of molecular responses and biodistri-
bution of therapeutic agents, including adenoviral vectors.
Another important consequence of cell culture in a 3D
environment is the enrichment of ‘cancer stem cell’ subpopu-
lations (94). Cancer stem cells represent rare subpopulations
that have important characteristics including the capacity
for autorenewal, tumor initiation and increased resistance to
chemotherapy. Evidence suggests that cancer stem cells are
the main cell type responsible for metastasis and tumor
repopulation after debulking in response to chemotherapy
(95-98). In 3D models of melanoma, a valuable strategy for
obtaining, and consequently studying, this subpopulation
is to culture melanocytes over extended periods of time
in modified culture media (99). The use of these strategies
contributes to physiologically relevant findings and greater
chances of success in clinical trials.
Ex vivo models for the activation of human
immune cells
Since our strategy relies on not only the induction of tumor
cell death but also the potential modulation of the tumor
microenvironment, especially the tumor immune environ-
ment, it is crucial to investigate this interaction. As long as
we use syngeneic mouse models, such assays are readily
available. However, the transition to human models, includ-
ing established cell lines or primary tumor samples, gives
rise to a critical issue when considering tumor-immune
interactions. In vivo models where human cells are implanted
in mice create a situation where immunodeficient animals are
necessary to minimize species incompatibility as described
above, although this also means that the immune response
cannot be evaluated. While mouse models with a humanized
immune system are available, they are quite complex and
associated with limitations in the emulated immune response
(100). Alternatively, in vitro models permit the evaluation of
specific aspects of the interaction between human immune
cells and human tumor cells that have undergone some
manipulation, such as gene transfer. Although such ex vivo
models still do not reproduce all of the facets of treating a
patient, they can reveal important aspects of the impact of
treatments on the microenvironment, thereby opening a
window to visualize important steps of immune activation.
In terms of the cancer-immunity cycle, our approach
targets the first step, that is, the killing of tumor cells while
releasing antigens and critical factors that activate DCs. As
described above, we can transfer p14ARF and hIFNb cDNA
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to established cell lines or primary samples. To model DC
activation, we isolate mononucleated cells from blood and
culture them with GM-CSF and IL-4 to induce the dif-
ferentiation of monocytes to DCs. At that point, it is possible
to modulate the maturation of the DCs by co-culture with
previously treated tumor cells. A mature DC is expected to
express co-stimulatory CD80, CD86, CD83 and MHC-II
molecules. The state of maturation is thought to be dependent
on the kind, duration and intensity of stimuli given to dif-
ferentiated DCs
In addition to the characterization of mature DCs based
on their immunophenotype, it is crucial to assess their ability
to activate naïve T cells, as DCs are known to induce the
T cell activation, marked by increased proliferation and
change in differentiation markers such as CD4, CD8, Foxp3,
RORgt, GATA-3 and T-bet. The activated T cells can then be
co-cultured with tumor cells in vitro to induce tumor cell
cytolysis and T cell proliferation. Ultimately, these activated
T cells can be transplanted into immunosuppressed tumor-
bearing mice used to generate the mature DCs to enable the
assessment of T cell homing to the tumor and the induction
of tumor cell death. Thus, the cancer-immunity cycle can be
explored, although some adaptations may be necessary.
A critical issue when using ex vivo models of DC and T cell
activation is the donor source used to acquire these cells.
To minimize immune differences, the tumor, DC and T cells
should come from the same patient. Nevertheless, DCs from
cancer patients have been shown to generate a Tcell response
associated with increased regulatory T (Treg) cells (101).
Moreover, the fusion of DCs with cancer cells has been shown
to be superior to simple mixing of DCs with tumor cells in
a vaccine model (102). Thus, the experimental design may
greatly influence the result obtained with respect to both DC
and T cell activation and functional assessment.
Beyond the mouse: preclinical testing of gene
therapy in canine melanoma
Few animal models recapitulate the entire cancer devel-
opmental process, starting with benign neoplasms, progres-
sing to primary tumors and giving rise to metastases. Most
murine models of human cancer involve the investigation of
certain aspects of the complex interactions among the tumor,
host and therapeutic modalities. As described above, we face
difficult choices between established mouse or human cell
lines and patient-derived cells since each of these cells has a
different genetic profile. In addition, we encounter a serious
limitation when human cells are implanted in immunodefi-
cient mice. However, the study of cancer in dogs represents
an important strategy in translational oncology. Spontaneous
cancer can develop in dogs due to their relatively long
life expectancy and exposure to environmental conditions
that are similar to those experienced by humans (103,104).
Dogs also have a complex immune system, including
mature immune development accompanied by typical Treg
cell responses (105).
In dogs, melanoma is the malignancy most commonly
found on the digits and in the oral cavity. Canine and human
melanomas share histological and biological similarities,
including cell morphology, disease progression and response
to therapies. Similar to human melanomas, canine melano-
mas are chemoresistant tumors (106).
Although not completely understood, the pathogenesis
of canine melanoma involves the loss of function of tumor
suppressor proteins, such as PTEN and p16/INK4a, common
alterations that contribute to the origin of this cancer in
both dogs and humans (107). BRAF is mutated in more than
56% of human cutaneous melanoma (108), but low rates of
mutations of this gene are described in canine (109) and
human mucosal melanoma (110). Both canine and human
mucosal melanoma show the activation of cancer-related
signaling pathways, such as AKT and MAPK, and are sen-
sitive to the inhibition of these pathways (111).
These biological similarities between canine and human
tumors may be responsible for the observed concordance in
treatment responses. In veterinary medicine, many of the
chemotherapy protocols are based on those used to treat
humans (112). Moreover, sequencing of the canine genome
was recently completed, and assay reagents and platforms
are now commercially available, creating an opportunity to
investigate tumor biology and drug response in dogs (113).
Therefore, spontaneously occurring tumors in dogs may be
considered preclinical models.
Various clinical trials of cancer therapies performed in
dogs complement the use of the typically used murine cancer
models for the development of new treatments (105,114-116).
For example, gene therapy using herpes simplex virus TK
and canine IFNb combined with a subcutaneously deli-
vered cellular vaccine expressing human IL-2 and GM-CSF
significantly prolonged disease-free and overall survival
while maintaining the quality of life of dogs with melanoma
(117). In another study, the administration of the adenovector
CD40L in stage III canine oral melanoma resulted in com-
plete remission with 2 intratumor injections before cytor-
eductive surgery (118).
For both veterinary patients and their owners, this is an
opportunity to participate in clinical trials of experimental
therapies. However, for humans, these trials in veterinary
patients are considered preclinical tests. This situation is
referred to as a co-clinical trial, where the same drug is tested
in both human and canine patients who have the same
tumor type or mutation spectrum (105). With regards to gene
therapy, co-clinical trials provide a unique opportunity to
reveal mechanisms of pathogenesis and to identify correla-
tions between outcomes in canines and humans.
Clinical trials in pets must be performed with informed
consent of their owners and must be approved by an accre-
dited animal care institute. The scientific motivation and
translational study must be balanced in relation to the ethical
and clinical perceptions of animal care. In general, pet dogs
are treated in studies with designs that are similar to those
used in clinical trials in human. However, the historical con-
ventions of phase I, II and III studies may be less rigid while
focus is maintained on developing the technical and bio-
logical aspects of the treatment strategy (119).
In the future, it is reasonable to expect clinical researchers
will view naturally occurring cancers in dogs and other ani-
mals as complementary models to the translational study of
new therapies. This approach may provide early toxicity
detection, optimization of clinical trial design, reduction of
costs and improvement in the future care of both canine and
human cancer patients.
Potential combinatorial approaches involving the
p19Arf + IFNb immunotherapy
Even though the experimental models described above
can provide an opportunity for us to investigate vectors
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encoding p14ARF and IFNb under conditions that more
closely resemble human cancer, it is reasonable to presume
that future translational approaches will most likely be applied
in combination with other treatment modalities, a practice
well established in the clinic for chemo, radio and targeted
therapies (120) and notably underscored by the combined use
of CTLA-4 and PD-1 checkpoint blockers (121).
Indeed, in view of the synergistic results obtained with
dual CTLA-4 and PD-1 blockade in melanoma, their com-
bined use was rapidly approved by the FDA and has
highlighted the capability of targeting multiple immune
pathways to provide benefit for patients who otherwise
would not respond to cancer immunotherapy (122). Combi-
natorial approaches are also expected to circumvent acquired
immunological resistance mechanisms and fuel the field of
immunotherapy to move steadily forward (122).
However, caution is warranted, as, along with improved
therapeutic results, there is a price to pay when targeting
multiple checkpoint modulators, with an increase in auto-
immunity and a series of immune-related adverse events
(123). Although in the case of p19Arf + IFNb gene transfer,
we have not observed any signs of an autoimmune response,
such as vitiligo in the melanoma model, we cannot rule out
the possibility that such responses may be generated. New
therapies, including ours, will require careful optimization
and development to avoid these toxicities while still induc-
ing antitumor immunity.
In fact, combinatorial strategies employing current and
novel immunotherapeutic modulators and their mechanisms
of action are being intensively studied in both preclinical and
clinical settings (122). Furthermore, regarding the potential
combinatorial approaches for our vectors, the immunomo-
dulatory functions exerted by IFNb are likely a critical target
to be exploited. For example, in melanoma, a type I IFN
signature correlated with CD8+ T cell infiltration and IFNb
production by tumor-associated DCs has been shown to be
critical for mediating antitumor immunity (124) This func-
tion may prove to be particularly useful for the so-called
cold tumors, which, in response to b-catenin signaling, lack
the production of CCL4 and fail to recruit CD103+ DCs and
produce IFNb within the tumor microenvironment and,
consequently, are deprived of the CXCL9/10 chemokines
that drive T cell influx (125). Accordingly, these nonin-
flamed tumors represent a challenge that current immu-
notherapeutic strategies have not yet been able to successfully
target. Moreover, type I IFNs are notorious for increasing
the expression of MHC-I molecules on tumor cells (126).
Therefore, if we were to consider the disruption in the
MHC-I pathway as a hallmark of immune evasion and
therapy inefficacy (127), the use of IFNb, especially under
conditions where its expression levels and dynamics are
controlled, could render tumor cells visible to the immune
system, avoiding primary resistance to subsequent combi-
natorial immunotherapies.
In addition to these immunomodulatory functions, type I
IFNs can promote different inhibitory mechanisms to regu-
late the amplitude and duration of the response, including
the production of the indoleamine 2,3-dioxygenase (IDO)
enzyme and, of special interest to our group, the expression
of PD-L1 in both tumors and tumor-infiltrating immune cells
(28,126). Although these inhibitory pathways may seem as
an impediment to our therapeutic approach at first, we
hypothesize that they actually create a potential opportunity
for us to combine checkpoint modulators with our treatment
regimen and ensure effective targeting of the IFNb-mediated
immunity cycle.
Combinatorial approaches can also augment cell death
or even modulate pathways involved in ICD, potentially
circumventing intrinsic defects or genetic alterations that
may affect the ability of treated cells to elicit optimal anti-
tumor immunity upon p19Arf + IFNb gene transfer. For
example, the use of other ICD inducers, such as doxorubicin
and mitoxantrone chemotherapy, could be an interesting
approach to induce caspase 3 activity along with the p19Arf+
IFNb necroptotic cell death and to change a resistant/non-ICD
scenario to a bona fide ICD or remediate the capability of
some agents to trigger ER stress responses, autophagy-
dependent accumulation of ATP and HMGB1 release from
the nucleus (128).
Our gene transfer approach promotes cell death and
immune stimulation, thus creating a variety of opportunities
for us to explore and optimize various aspects, including the
development of vaccination strategies and the direct applica-
tion of our vectors into the tumor mass. Nevertheless, many
key aspects remain to be investigated, most importantly, the
use of patient-derived tumor and immune cells to validate
the evidence gathered from mouse models and the explora-
tion of tumor responses in alternative models, such as spon-
taneously arising cancers in dogs. In terms of technological
development, the production of viruses of pharmaceutical
quality, that is, by following good manufacturing practices
(GMP), is a critical step that is not currently available in
Brazil. Nonetheless, the know-how required to conduct
preclinical studies and clinical trials is readily available in
our community and may be further supported by interna-
tional collaborations.
The translational road ahead of us is long but certainly
exciting. The goal of translational medicine is to evaluate
therapeutic strategies that are successfully developed in
preclinical models in clinical trials performed in humans. In
addition, although we envision it as a straightforward path,
the translational road should be seen as a two way road, with
exchange of information between the bench and bedside, and
vice versa. In this regard, it is critical that a multidisciplinary
team of basic and clinical scientists work together to ensure
that a clinically relevant and viable approach is developed as
we progress along the road of translational research.
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